HOME >> BIOLOGY >> NEWS
Epigenetic drugs, promising for breast cancer treatment

Worldwide, cancer persists as one of the most important diseases that affect the human being. The knowledge on the molecular bases of cancer generated during the last decades has been successfully translated into small but significant gains in overall cancer survival rates due to better primary prevention measures, improved diagnostic methods and the development of more effective and specific therapies, collectively termed "molecular targeted therapies". In the context of these new forms of treatment, epigenetic or transcriptional cancer therapy is clearly promising.

Epigenetics refers to the function of DNA that does not depend on the coding DNA sequence itself but on the accessory molecules and mechanisms affected by DNA. It is known that epigenetic alterations are equally if not more important than classical genetic alterations to disrupt the function of tumour suppressor genes. The two most studied epigenetic aberrations common to all types of cancer are DNA hypermethylation and histone deacetylation, which cooperate to silence the expression of tumour suppressor genes, just as gene mutations and gene deletions do. The big difference between these two alternative ways that tumour cells use to inactivate tumour suppressor genes is that, while the reversal of genetic alterations is technically almost unfeasible in clinical scenarios, the function of these epigenetically inactivated suppressor genes is easily reactivated by pharmacological means. In this inaugural issue of PLoS ONE, Dr. Dueas-Gonzalez's group from the Instituto de Investi gaciones Biomdicas of the Universidad Nacional Autnoma de Mxico and the Instituto Nacional de Cancerologa, Mexico, demonstrate, for the first time, that a combination of a DNA methylation and a histone deacetylase inhibitor, can reactivate the expression of more than a thousand genes in primary tumours of breast cancer patients.

Among these reactivated genes are those implicated in the regulation of cell pr
'"/>

Contact: Rosalba Namihira
namihira@biomedicas.unam.mx
52-155-297-22352
Public Library of Science
20-Dec-2006


Page: 1 2 3

Related biology news :

1. Epigenetic studies will provide a better understanding of disease
2. Epigenetics to shape stem cell future
3. New view of cancer: Epigenetic changes come before mutations
4. Epigenetic activity silences Rb2/P130 gene in lung cancer
5. A new plant-bacterial symbiotic mechanism promising
6. A new plant-bacterial symbiotic mechanism promising for crop applications
7. American Association for Cancer Research provides support for promising cancer scientists
8. Sea creatures toxin could lead to promising cancer treatment
9. New study suggests promising drug combinations for sleeping sickness
10. Analysis of breast-cancer gene role offers promising target
11. Researchers report initial success in promising approach to prevent tooth decay

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2020)... ... February 13, 2020 , ... ... geared to clinical operations executives and focusing on all facets of clinical trial ... portfolio management, patient engagement, and more. , “We have attended the SCOPE ...
(Date:2/11/2020)... ... 11, 2020 , ... Modality Solutions, a leading ... 9001:2015 registration by certification body Intertek. Modality Solutions’ Quality Manager, Hannah Anderson, spearheaded ... existing Standard Operating Procedures (SOPs) and created ten new SOPs. Anderson trained staff ...
(Date:2/11/2020)... ... 11, 2020 , ... The LaunchPort™ announced today that ExoRenal ... Covington, Baltimore. The newly formed company is developing a novel pulsatile hemodialysis technology ... for home dialysis treatments. The start-up company will be moving research functions from ...
Breaking Biology News(10 mins):
(Date:2/3/2020)... ... 2020 , ... Ovation Travel Group has published ... Travel and Biotech/Healthcare Industry Travel Indexes. , All of the Indexes contain three ... Average airfare price paid Domestically, Internationally and Overall , ...
(Date:1/28/2020)... ... January 28, 2020 , ... ... distributor to food and beverage manufactures within North America. Both Lifecycle and Midland ... agreement will allow each company to pool their collective resources and provide the ...
(Date:1/28/2020)... Pa. (PRWEB) , ... January 28, 2020 , ... ... of Better Salivary Assay Kits . The new Salivary Total Human ... research. “By measuring total immunoglobulin G in saliva, researchers can extend the accuracy ...
(Date:1/27/2020)... ... January 27, 2020 , ... Valencell, the leading innovator ... investors led by Halma plc , a FTSE 100 global group of ... LLC, and WSJ Joshua Fund. A representative from Halma will join the Valencell ...
Breaking Biology Technology:
Cached News: